Moderna’s Patent Estate: Messenger RNA Technologies (mRNA) & Delivery Technologies
Moderna has pioneered the development of modified messenger RNA (mRNA) medicines since our founding. We are a leader in the space, having advanced more than 20 programs using modified mRNA technologies into development. As of October 2020, we have announced ten clinical programs for internal and partnered mRNA therapeutics and vaccines.
Along the way, we have amassed a broad and deep patent estate. This includes foundational patents in modified mRNA technologies and delivery technologies that are essential for mRNA therapeutics and vaccines, including their application in specific unmet needs in infectious diseases, cancer (immuno-oncology), and rare and cardiometabolic diseases, among others.
To date, Moderna has been granted more than 240 patents in the United States, Europe, Japan and other jurisdictions, protecting fundamental inventions in the mRNA therapeutics space, with several hundred additional pending patent applications covering key advances in the field. We have augmented our internal patent estate with several in-licensed patent estates, including licenses to pioneering discoveries from Harvard University and the University of Pennsylvania.
We continue to invest aggressively in science and technology to build a broader patent portfolio and ensure Moderna is in the strongest possible position to deliver on the promise of mRNA to bring a new class of transformative medicines to patients in the decades to come.
A statement by Moderna on Intellectual Property Matters during the COVID-19 Pandemic can be found here. Representative US patents relevant to our mRNA-1273 vaccine against COVID-19, are available here.